TapewireFind a company

person · Reporting owner

Foster Karen A.

Disclosed activity across 1 company

Tapewire entity
55204
SEC CIK
0001683151

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
BIOLIFE SOLUTIONS INCBLFS · Entity 4614Chief Quality and OperationsMarch 23, 2026March 31, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIOLIFE SOLUTIONS INC

Report date March 23, 2026 · Filed March 31, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect108,758 Reported balance After 2026-03-23 transaction · row 1
1 source row

Row 1 · 2026-03-23 · Sale · Disposed 2,577 · Balance 108,758

F1: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Filing footnotes · ownership attribution and instrument terms

F1: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 23, 2026 Filed Mar 31, 2026 21:19 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 2,577 $19.17 $49,401.09
Disclosure

SEC source: 0001628280-26-022501 · wk-form4_1774991982.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,758

F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-04-2025

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.99 to $19.35, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 19, 2026 Filed Mar 23, 2026 21:08 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Tax withholdingCommon Stock 1,907 $19.12 $36,461.84
Disclosure

SEC source: 0001628280-26-020576 · wk-form4_1774300110.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,335

F1 · price: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.

Read SEC document
March 09, 2026 Filed Mar 9, 2026 22:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 500 $20.00 $10,000.00
Disclosure

SEC source: 0001628280-26-016165 · wk-form4_1773094257.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,242

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.02, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 05, 2026 Filed Mar 9, 2026 22:11 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 96,923 $20.15 $1,952,998.45
Disclosure

SEC source: 0001628280-26-016165 · wk-form4_1773094257.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,742

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.46, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Read SEC document
March 03, 2026 Filed Mar 5, 2026 22:10 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 418 $20.74 $8,669.32
Disclosure

SEC source: 0001628280-26-015341 · wk-form4_1772748626.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 210,665

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 24, 2026 Filed Feb 26, 2026 22:55 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 Tax withholdingCommon Stock 13,013 $22.65 $294,744.45
Disclosure

SEC source: 0001628280-26-012469 · wk-form4_1772146509.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 211,083

F2 · price: Represents shares withheld to cover tax withholding obligations in connection with the vesting of the market-based restricted stock award.

Read SEC document
February 24, 2026 Filed Feb 26, 2026 22:55 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 32,112 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-26-012469 · wk-form4_1772146509.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,096

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to approximately 156% of the number of shares granted based on the registrant's total shareholder return during the period beginning on January 1, 2024 through December 31, 2025 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
January 06, 2026 Filed Jan 8, 2026 22:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 335 $25.59 $8,572.65
Disclosure

SEC source: 0001628280-26-001385 · wk-form4_1767909860.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 191,984

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
December 09, 2025 Filed Dec 17, 2025 22:25 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 519 $25.13 $13,042.47
Disclosure

SEC source: 0001628280-25-057719 · wk-form4_1766010343.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 192,319

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 25, 2025 Filed Nov 28, 2025 22:35 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 415 $26.74 $11,097.10
Disclosure

SEC source: 0001628280-25-054280 · wk-form4_1764369320.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 192,838

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 09, 2025 Filed Oct 14, 2025 21:30 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 419 $27.36 $11,463.84
Disclosure

SEC source: 0001628280-25-045015 · wk-form4_1760477418.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,253

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
September 11, 2025 Filed Sep 15, 2025 21:02 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 511 $26.83 $13,710.13
Disclosure

SEC source: 0001683151-25-000003 · wk-form4_1757970140.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 193,672

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 26, 2025 Filed Aug 28, 2025 21:07 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 413 $25.44 $10,506.72
Disclosure

SEC source: 0001628280-25-041303 · wk-form4_1756415242.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,183

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 07, 2025 Filed Jul 9, 2025 21:54 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 400 $22.27 $8,908.00
Disclosure

SEC source: 0001628280-25-034684 · wk-form4_1752098067.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,596

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
June 10, 2025 Filed Jun 12, 2025 21:23 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 320 $23.70 $7,584.00
Disclosure

SEC source: 0001628280-25-031097 · wk-form4_1749763422.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 194,996

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 28, 2025 Filed May 30, 2025 22:09 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 251 $22.46 $5,637.46
Disclosure

SEC source: 0001628280-25-028708 · wk-form4_1748642829.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,316

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 09, 2025 Filed Apr 11, 2025 21:49 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 286 $20.11 $5,751.46
Disclosure

SEC source: 0001628280-25-017585 · wk-form4_1744408136.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,567

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 01, 2025 Filed Apr 3, 2025 21:48 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 7,869 $22.66 $178,311.54
Disclosure

SEC source: 0001628280-25-016634 · wk-form4_1743716886.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 195,853

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 18, 2025 Filed Mar 20, 2025 23:08 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 29,711 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,722

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 175% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2023 through December 31, 2024 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 18, 2025 Filed Mar 20, 2025 23:08 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 19,099 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-25-014187 · wk-form4_1742512119.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,011

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2025 compensation.

Read SEC document
March 11, 2025 Filed Mar 13, 2025 21:26 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,331 $25.00 $33,275.00
Disclosure

SEC source: 0001628280-25-012678 · wk-form4_1741901158.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 154,912

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 22:13 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 324 $25.46 $8,249.04
Disclosure

SEC source: 0001628280-25-010566 · wk-form4_1741212823.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,243

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
February 12, 2025 Filed Feb 14, 2025 22:46 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 78 $26.54 $2,070.12
Disclosure

SEC source: 0001628280-25-005842 · wk-form4_1739573206.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,567

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 06, 2025 Filed Jan 9, 2025 00:10 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 328 $27.02 $8,862.56
Disclosure

SEC source: 0001628280-25-000983 · wk-form4_1736381429.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,645

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 26, 2024 Filed Nov 29, 2024 22:29 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 252 $27.20 $6,854.40
Disclosure

SEC source: 0001628280-24-049476 · wk-form4_1732919366.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,973

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 12, 2024 Filed Nov 14, 2024 23:38 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 66 $26.34 $1,738.44
Disclosure

SEC source: 0001628280-24-047994 · wk-form4_1731627476.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,225

F1 · shares: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
October 30, 2024 Filed Nov 1, 2024 23:01 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 277 $23.15 $6,412.55
Disclosure

SEC source: 0001628280-24-044813 · wk-form4_1730502101.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,291

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-23 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
September 16, 2024 Filed Sep 18, 2024 21:45 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 267 $25.12 $6,707.04
Disclosure

SEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 3

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,568

F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
August 21, 2024 Filed Sep 18, 2024 21:45 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 96 $25.61 $2,458.56
Disclosure

SEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,835

F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
July 18, 2024 Filed Sep 18, 2024 21:45 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 240 $22.50 $5,400.00
Disclosure

SEC source: 0001628280-24-040834 · wk-form4_1726695926.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 157,931

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 29, 2024 Filed May 31, 2024 21:05 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 408 $21.78 $8,886.24
Disclosure

SEC source: 0001628280-24-026084 · wk-form4_1717189544.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,171

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
May 17, 2024 Filed May 21, 2024 12:13 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 85 $22.18 $1,885.30
Disclosure

SEC source: 0001628280-24-024446 · wk-form4_1716293584.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,579

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
April 18, 2024 Filed Apr 23, 2024 23:14 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 481 $15.31 $7,364.11
Disclosure

SEC source: 0001628280-24-017498 · wk-form4_1713914077.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 158,664

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 27, 2024 Filed Mar 29, 2024 21:39 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 395 $17.99 $7,106.05
Disclosure

SEC source: 0001628280-24-013828 · wk-form4_1711748356.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,145

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 12, 2024 Filed Mar 13, 2024 01:43 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 5,177 $16.60 $85,938.20
Disclosure

SEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 4

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 159,540

F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 11, 2024 Filed Mar 13, 2024 01:43 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 319 $17.42 $5,556.98
Disclosure

SEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 3

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 164,717

F3 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:43 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 20,445 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 165,036

F2 · price: The restricted stock was granted pursuant to the 2013 Performance Incentive Plan. In accordance with the terms of the grant, the restricted stock vested as to 125% of the reported number of shares reported in the reporting person's Form 4 reporting the grant based on the registrant's total shareholder return during the period beginning on January 1, 2022 through December 31, 2023 as compared to the total shareholder return of certain of the registrant's peers (such peers have been determined by the registrant's compensation committee with assistance of an outside consultant immediately prior to the grant date).

Read SEC document
March 08, 2024 Filed Mar 13, 2024 01:43 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 20,651 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-24-010742 · wk-form4_1710294154.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 144,591

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan (the "2023 Plan") and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2024 compensation.

Read SEC document
February 21, 2024 Filed Feb 23, 2024 22:50 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 87 $17.35 $1,509.45
Disclosure

SEC source: 0001628280-24-006705 · wk-form4_1708728647.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,940

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 19, 2024 Filed Jan 23, 2024 22:30 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 1,198 $16.76 $20,078.48
Disclosure

SEC source: 0001628280-24-001985 · wk-form4_1706049023.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,027

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
January 02, 2024 Filed Jan 4, 2024 22:04 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 601 $16.75 $10,066.75
Disclosure

SEC source: 0001628280-24-000470 · wk-form4_1704405875.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality and Operations

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,225

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
December 17, 2023 Filed Dec 19, 2023 22:54 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 228 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-042030 · wk-form4_1703026465.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,568

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
December 03, 2023 Filed Dec 21, 2023 20:44 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 258 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-042481 · wk-form4_1703191474.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,826

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 00:15 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 466 $12.37 $5,764.42
Disclosure

SEC source: 0001628280-23-040677 · wk-form4_1701735316.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,340

F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-24-2022 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 19, 2023 Filed Dec 5, 2023 00:15 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 267 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-040677 · wk-form4_1701735316.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,806

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
November 13, 2023 Filed Nov 15, 2023 15:41 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 114 $10.77 $1,227.78
Disclosure

SEC source: 0001628280-23-039100 · wk-form4_1700062902.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,539

F1 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 02-08-2021 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document
November 05, 2023 Filed Nov 13, 2023 21:41 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 299 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-038654 · wk-form4_1699911667.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,653

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
October 22, 2023 Filed Oct 24, 2023 23:46 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 335 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-035029 · wk-form4_1698191164.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,354

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
October 08, 2023 Filed Oct 10, 2023 21:25 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 GrantCommon Stock 252 Not disclosed Not disclosed
Disclosure

SEC source: 0001628280-23-034201 · wk-form4_1696973135.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,019

F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash salary at the last closing price as of the date of grant.

Read SEC document
September 28, 2023 Filed Oct 2, 2023 21:08 UTC BIOLIFE SOLUTIONS INC BLFS · Entity 4614 SaleCommon Stock 568 $14.16 $8,042.88
Disclosure

SEC source: 0001628280-23-033511 · wk-form4_1696280929.xml · nonDerivative · entry 2

Foster Karen A. · CIK 0001683151 · Chief Quality Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 124,767

F2 · kind: The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-25-2020 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.